Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2...
December 03 2020 - 9:15AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today announced
its CEO, Maria Maccecchini, Ph.D., will present at the
New York Academy of Sciences’ Alzheimer's
Disease Therapeutics: Alternatives to Amyloid 2020 Virtual
Conference on Friday, December 4, 2020.
Dr. Maccecchini’s presentation, “Targeting
Increased Levels of Neurotoxic Proteins in Down Syndrome,
Alzheimer’s and Parkinson’s Animals Normalized Axonal Transport,
Cognition and Function,” will highlight the Company’s data that
demonstrates by lowering amyloid, tau, and alpha-synuclein, the
Company’s lead candidate, ANVS401, restores axonal transport and
nerve cell health.
“Our approach to neurodegeneration is unique
when compared to the long list of failed trials exclusively
targeting amyloid,” stated Dr. Maccecchini. “I am excited to share
our promising data with the conference attendees at this first
major event of its type dedicated to non-amyloid approaches to
AD.”
ANVS401 inhibits more than one neurotoxic
protein and, thereby, improves axonal transport and reverses the
toxic cascade leading to nerve cell death. The Company is presently
in two ongoing double-blind, placebo-controlled Phase 2a studies
that were designed to measure the toxic cascade that leads to nerve
cell death and expects preliminary data in both AD and PD patients
in the first half of 2021.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and have commenced a second Phase 2a study in AD and PD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate, including that
clinical trials may be delayed. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2023 to Apr 2024